BackAbiomed Overview

Abiomed Current Cash

Track Abiomed's current cash ($820M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$820.37M
↑ 26.10% YoYΔ $169.81M vs prior year quarter

Peer average

Loading

Abiomed Current Cash History

Loading

Abiomed vs. peers: Current Cash Comparison

Loading

Abiomed Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Abiomed (ABMD) FAQ

As of the most recent data (September 2022), ABMD shows a current cash of $820M. That compares with $650M in the prior-year period — up 26.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ABMD's current cash is now $820M (was $650M) — a 26.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Abiomed is outperforming or lagging.

Tracking ABMD's current cash over time shows whether Abiomed is scaling, shrinking, or reshaping that part of the business. The current reading is $820M That compares with $650M in the prior-year period — up 26.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Abiomed's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $820M) with ownership activity and broader fundamentals.

Abiomed's current cash is $820M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.